Saanroo's Trpti Shows Rapid GLP-1/GIP Response; Impacts Weight Management Formulations
A new single-blind clinical trial for Saanroo's Trpti ingredient demonstrates rapid post-meal GLP-1 and GIP increases, positioning it as a key component for next-generation weight management and metabolic health supplements.
London, United Kingdom — 15 May 2024
Saanroo's Trpti, a bioavailable oleoylethanolamide (OEA) ingredient, has demonstrated significant post-meal increases in glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) responses, according to a recent single-blind human clinical trial. This trial, focused on healthy adults with overweight to obese BMI, highlights Trpti's role in supporting nutrient sensing and the body’s natural incretin response, crucial for metabolic health and weight management.
The study specifically found that a single 300 mg dose of Trpti led to a significant increase in both GLP-1 and GIP within 15 minutes of ingestion, compared to a placebo. Saanroo reports that this effect was sustained and reoccurred after subsequent meals, suggesting a consistent physiological impact. This rapid and sustained response offers a compelling proposition for supplement manufacturers aiming to develop efficacious weight management products, providing a tangible mechanism of action beyond traditional fibre or stimulant-based approaches.
The emphasis on 'nutrient sensing' and 'incretin response' positions Trpti in a nascent but growing area of metabolic health science, moving beyond simple calorie restriction. This scientific substantiation provides formulators with robust data to support novel product claims and differentiate offerings in a competitive market. Given the escalating consumer demand for evidence-backed solutions, ingredients like Trpti, with demonstrated clinical efficacy in key metabolic pathways, are becoming increasingly valuable.
What this means for United Kingdom
UK brand owners must rapidly evaluate Trpti for inclusion in their weight management and metabolic health portfolios. The ingredient's 15-minute onset of action offers a strong marketing claim for consumer-facing products, enabling differentiation within the competitive Boots and Holland & Barrett retail channels. Procurement leads should anticipate MOQs and lead times from Saanroo, integrating a 300 mg dose into formulation costs and capsule specifications. This presents an opportunity for innovative brands to command higher price points by offering clinically substantiated, rapid-acting solutions to the approximately 64% of UK adults classified as overweight or obese, who are actively seeking effective interventions.
The trial's findings underpin a strategic opportunity for brands to reformulate existing products or launch new lines that address the growing consumer interest in metabolic balance. Regulatory teams should ensure that all marketing claims are meticulously aligned with the published clinical data to maintain compliance with MHRA and ASA guidelines, avoiding unsubstantiated references to weight loss and focusing on metabolic support.
Many leading brands in this category are manufactured in partnership with Supplement Factory.